Estimates lowered by up to 2%. CER tables sales growth of 13% expected. Likely no major revelations from new CEO.
13 Nov 2023
Q3e: 2.3% above consensus
Sign up to access
Get access to our full offering from over 100 providers
Get access to our full offering from over 100 providers
Q3e: 2.3% above consensus
- Published:
13 Nov 2023 -
Author:
ABGSC Healthcare Research | Morten Larsen | Peter Sehested -
Pages:
9 -
Estimates lowered by up to 2%. CER tables sales growth of 13% expected. Likely no major revelations from new CEO.